Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain-Reference-Cited by-同舟云学术

Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain

Published:2013-06-11 Issue:6 Volume:19 Page:841-846
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Jimenez-Yuste V.¹,Núñez R.²,Romero J. A.¹,Montoro B.³,Espinós B.⁴

Affiliation:

1. Hospital Universitario La Paz; Autonoma University; Madrid Spain

2. Hospital Virgen del Rocío; Sevilla Spain

3. Hospital Vall d'Hebron; Barcelona Spain

4. IMS Health; Barcelona Spain

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hae.12199/fullpdf

Reference23 articles.

1. The hemophilias-from royal genes to gene therapy;Mannucci;N Engl J Med,2001

2. Haemophilia in Spain;Aznar;Haemophilia,2009

3. Prophylaxis therapy in haemophilia A: current situation in Spain;Lucía;Haemophilia,2011

4. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain;Batlle;Blood Coagul Fibrinolysis,2008

5. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors;Young;Haemophilia,2005

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacoeconomic Aspects in Hemophilia;Advances in Hemophilia Treatment;2022

2. The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality;Expert Review of Hematology;2020-01-22

3. Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico;Value in Health Regional Issues;2018-12

4. The socioeconomic burden of patients affected by hemophilia with inhibitors;European Journal of Haematology;2018-07-27

5. Inhibitors in Hemophilia A: A Pharmacoeconomic Perspective;Seminars in Thrombosis and Hemostasis;2017-12-08